IE
MBRX icon

Israel Englander’s Moleculin Biotech MBRX Stock Holding History

Israel Englander’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-81
Closed -$13K – 6347
2023
Q3 		$13K Sell
81
-9
-10% -$1.86K ﹤0.01% 5721
2023
Q2 		$19.5K Buy
+90
New +$23.7K ﹤0.01% 5637
2020
Q4 		– Sell
-93
Closed -$171 – 5433
2020
Q3 		$171 Buy
+93
New +$198K ﹤0.01% 4111
2020
Q1 		– Sell
-43
Closed -$88K – 4231
2019
Q4 		$88K Sell
43
-52
-55% -$122K ﹤0.01% 4043
2019
Q3 		$237K Buy
+95
New +$245K ﹤0.01% 3700

Other funds holding MBRX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AWM
Atticus Wealth Management Palm Beach Gardens, Florida $420M AUM 23.31% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Israel Englander's MBRX Position: Q4 2023 in Review

Israel Englander sold out of Moleculin Biotech (MBRX) in Q4 2023, closing a stake of 81 shares — an estimated $13K sold.

Israel Englander first reported a position in MBRX in Q3 2019 and held it in 5 quarters. The position peaked at $237K in Q3 2019. 20 funds tracked by Wall St. Rank hold MBRX as of Q4 2023.

  • Israel Englander reported no remaining Moleculin Biotech position as of Q4 2023 after selling out during the quarter.
  • Israel Englander sold 81 Moleculin Biotech shares in Q4 2023, an estimated $13K.
  • Israel Englander first reported a position in Moleculin Biotech in Q3 2019 and held it in 5 quarters.
  • Israel Englander's Moleculin Biotech position peaked at $237K in Q3 2019.
  • 20 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.